BioCentury | Jul 3, 2020
Finance

On heels of $100M raise, Annexon joins burgeoning IPO queue

...submit an IND this year for INZ-701, an enzyme replacement therapy to treat ENPP1 and ABCC6...
...$21 million. Staff Writer Hongjiang Li contributed to this report. Targets ABCC6 (MRP6; PXE) - ATP-binding cassette sub-family C member 6...
BioCentury | Oct 25, 2019
Product Development

Lykera takes aim at aggressive cancers by targeting pre-metastatic niche

Lykera joins a growing wave of companies targeting the tumor stroma, but it is taking a different approach with a portfolio of first-in-class mAbs against S100 proteins implicated in driving metastases. Its lead programs are...
BioCentury | Sep 10, 2019
Distillery Therapeutics

S100A9 could normalize metabolic imbalances from insulin deficiency

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Diabetes Promoting expression of S100A9, a plasma protein induced by leptin, could treat diabetes. Type I and Type II diabetes induce insulin deficiency, which causes metabolic imbalances including hyperglycemia, hyperglucagonemia, hyperketonemia,...
BioCentury | May 28, 2019
Distillery Therapeutics

Split intein-based gene therapies for two types of congenital blindness

DISEASE CATEGORY: Ophthalmic disease INDICATION: Blindness Mouse studies suggest gene therapies delivering ABCA4 or CEP290 as split inteins could help treat Stargardt disease or Leber congenital amaurosis type 10 (LCA10), respectively. The therapies consist of...
BioCentury | May 6, 2019
Financial News

May 6 Financial Quick Takes: Athenex, Spiral

Athenex raises $100M to advance Oraxol Looking to fund commercialization activities for Oraxol and advance its oncology pipeline and actinic keratosis therapy, Athenex Inc. (NASDAQ:ATNX) raised $100 million in a private placement through the sale...
BioCentury | Feb 8, 2019
Company News

Sanofi seeking partner to develop Oxford BioMedica's ophthalmology gene therapies

Oxford BioMedica plc (LSE:OXB) said Sanofi (Euronext:SAN; NASDAQ:SNY) will seek a partner to continue further development of two ophthalmology gene therapy programs that the pharma gained under a 2009 deal with Oxford BioMedica. The products...
BioCentury | Aug 10, 2018
Clinical News

Active, Teva's laquinimod misses in Phase II for HD

Active Biotech AB (SSE:ACTI) said once-daily 1 mg oral laquinimod missed the primary endpoint of improving the Unified Huntington's Disease Rating Scale - Total Motor Score (UHDRS-TMS) from baseline to 12 months vs. placebo in the...
BioCentury | Jul 11, 2018
Translation in Brief

Poisoning the stromal chalice

A study published in the Journal of Clinical Investigation suggests antibody-drug conjugates targeting the tumor stroma could treat cancers by co-opting a stromal mechanism to feed cytotoxic drugs to the surrounding tumor cells. Tumor-associated stroma,...
BioCentury | Jun 8, 2018
Company News

Opthotech gains gene therapy for ophran vision-loss disease

Ophthotech Corp. (NASDAQ:OPHT) acquired exclusive, worldwide rights to develop and commercialize a preclinical ophthalmic gene therapy from the University of Florida Research Foundation and the University of Pennsylvania. The deal gives the biotech an adeno-associated...
BioCentury | Jun 7, 2018
Company News

Ophthotech gains gene therapy for orphan vision-loss disease

Ophthotech Corp. (NASDAQ:OPHT) gained $0.29 (10%) to $3.09 on Thursday on news that it acquired exclusive, worldwide rights to develop and commercialize a preclinical ophthalmic gene therapy from the University of Florida Research Foundation and...
Items per page:
1 - 10 of 183